Stock Track | Amneal Pharmaceuticals Plummets 6.39% as Tepid Guidance Overshadows Q2 Beat

Stock Track07-30 21:49

Amneal Pharmaceuticals, Inc. (AMRX) shares plummeted 6.39% intraday on Thursday, reversing sharp premarket gains, as investors zeroed in on the company's full-year outlook, which failed to match the enthusiasm sparked by its second-quarter results.

The drugmaker reported adjusted earnings of $0.30 per share for the second quarter, handily beating the consensus estimate of $0.22. Revenue came in at $796 million. The strong results initially sent the stock soaring more than 10% in premarket trading. However, the rally evaporated after the company issued its full-year 2026 guidance, which included an adjusted EPS range of $0.96 to $1.06, only slightly above the FactSet estimate of $0.97 at the midpoint. The company also forecast full-year revenue of $3.1 billion to $3.2 billion and capital expenditures of $150 million.

The muted guidance raise, despite a significant quarterly beat, appeared to disappoint investors who may have expected a more robust upgrade to the annual forecast. The sell-off during the regular session wiped out all premarket gains and then some, with the stock falling to a decline of over 6%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1158761734?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-30 21:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1158761734","market":"us","top_or_hot":-1,"title":"Stock Track | Amneal Pharmaceuticals Plummets 6.39% as Tepid Guidance Overshadows Q2 Beat","media":"Stock Track","content":"<p>Amneal Pharmaceuticals, Inc. (AMRX) shares plummeted 6.39% intraday on Thursday, reversing sharp premarket gains, as investors zeroed in on the company's full-year outlook, which failed to match the enthusiasm sparked by its second-quarter results.</p><p>The drugmaker reported adjusted earnings of $0.30 per share for the second quarter, handily beating the consensus estimate of $0.22. Revenue came in at $796 million. The strong results initially sent the stock soaring more than 10% in premarket trading. However, the rally evaporated after the company issued its full-year 2026 guidance, which included an adjusted EPS range of $0.96 to $1.06, only slightly above the FactSet estimate of $0.97 at the midpoint. The company also forecast full-year revenue of $3.1 billion to $3.2 billion and capital expenditures of $150 million.</p><p>The muted guidance raise, despite a significant quarterly beat, appeared to disappoint investors who may have expected a more robust upgrade to the annual forecast. The sell-off during the regular session wiped out all premarket gains and then some, with the stock falling to a decline of over 6%.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Amneal Pharmaceuticals Plummets 6.39% as Tepid Guidance Overshadows Q2 Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Amneal Pharmaceuticals Plummets 6.39% as Tepid Guidance Overshadows Q2 Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-07-30 21:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Amneal Pharmaceuticals, Inc. (AMRX) shares plummeted 6.39% intraday on Thursday, reversing sharp premarket gains, as investors zeroed in on the company's full-year outlook, which failed to match the enthusiasm sparked by its second-quarter results.</p><p>The drugmaker reported adjusted earnings of $0.30 per share for the second quarter, handily beating the consensus estimate of $0.22. Revenue came in at $796 million. The strong results initially sent the stock soaring more than 10% in premarket trading. However, the rally evaporated after the company issued its full-year 2026 guidance, which included an adjusted EPS range of $0.96 to $1.06, only slightly above the FactSet estimate of $0.97 at the midpoint. The company also forecast full-year revenue of $3.1 billion to $3.2 billion and capital expenditures of $150 million.</p><p>The muted guidance raise, despite a significant quarterly beat, appeared to disappoint investors who may have expected a more robust upgrade to the annual forecast. The sell-off during the regular session wiped out all premarket gains and then some, with the stock falling to a decline of over 6%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMRX","symbol_name":"Amneal Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1158761734","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1158761734","pubTimestamp":1785419366,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Amneal Pharmaceuticals, Inc. (AMRX) shares plummeted 6.39% intraday on Thursday, reversing sharp premarket gains, as investors zeroed in on the company's full-year outlook, which failed to match the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AMRX":"Amneal Pharmaceuticals, Inc."},"translate_title":"股票跟踪 | Amneal Pharmaceuticals 股价暴跌 6.39%，不温不火的指导给第二季度业绩蒙上阴影","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMRX":1},"content_text":"Amneal Pharmaceuticals, Inc. (AMRX) shares plummeted 6.39% intraday on Thursday, reversing sharp premarket gains, as investors zeroed in on the company's full-year outlook, which failed to match the enthusiasm sparked by its second-quarter results.The drugmaker reported adjusted earnings of $0.30 per share for the second quarter, handily beating the consensus estimate of $0.22. Revenue came in at $796 million. The strong results initially sent the stock soaring more than 10% in premarket trading. However, the rally evaporated after the company issued its full-year 2026 guidance, which included an adjusted EPS range of $0.96 to $1.06, only slightly above the FactSet estimate of $0.97 at the midpoint. The company also forecast full-year revenue of $3.1 billion to $3.2 billion and capital expenditures of $150 million.The muted guidance raise, despite a significant quarterly beat, appeared to disappoint investors who may have expected a more robust upgrade to the annual forecast. The sell-off during the regular session wiped out all premarket gains and then some, with the stock falling to a decline of over 6%.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1158761734","isCrawlerRequest":true}